Llwytho...
Therapeutic cancer vaccines and combination immunotherapies involving vaccination
Recent US Food and Drug Administration approvals of Provenge(®) (sipuleucel-T) as the first cell-based cancer therapeutic factor and ipilimumab (Yervoy(®)/anticytotoxic T-lymphocyte antigen-4) as the first “checkpoint blocker” highlight recent advances in cancer immunotherapy. Positive results of th...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Immunotargets Ther |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove Medical Press
2014
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918241/ https://ncbi.nlm.nih.gov/pubmed/27471705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S40264 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|